Rani Therapeutics Holdings (RANI) Price to Sales (2024 - 2026)

Rani Therapeutics Holdings has reported Price to Sales for 3 years, with the latest figure at 83.28 in Q2 2026.

• On a quarterly basis, Price to Sales changed N/A year-over-year to 83.28 in Q2 2026; TTM through Jun 2026 was 29.17, a 8.58% increase from a year earlier, with the FY2025 full-year figure at 100.52, up 31.4% from the prior year.
• Price to Sales was 83.28 for Q2 2026 at Rani Therapeutics Holdings, up from 77.98 in the prior quarter.
• The five-year high for Price to Sales was 421.53 in Q1 2025, with the low at 76.5 in Q4 2024.
• Average Price to Sales over 3 years is 154.33, with a median of 83.28 recorded in 2026.
• The sharpest annual moves came in 2025 and 2026: Price to Sales soared 46.87% in 2025, then slumped 81.5% in 2026.
• Over 3 years, Price to Sales stood at 76.5 in 2024, then jumped by 46.87% to 112.35 in 2025, then slipped by 25.87% to 83.28 in 2026.
• The last three Price to Sales figures came in at 83.28 (Q2 2026), 77.98 (Q1 2026), and 112.35 (Q4 2025), per Business Quant data.